InVivoMAb大鼠IgG2a同種型對照：專用于三硝基苯酚免疫反應性研究

2A3單克隆抗體與三硝基苯酚反應。由于哺乳動物不表達三硝基苯酚，這種抗體非常適合在大多數體內和體外應用中用作大鼠IgG2a抗體的同種型匹配對照。

艾美捷InVivoMAb大鼠IgG2a同種型對照，抗三硝基苯酚：

貨號：BXC-BE0089

亞型：大鼠IgG2a，κ

由LAL凝膠凝固測定法確定

推薦稀釋液：InVivoPure pH 6.5稀釋液

偶聯：未偶聯。提供抗體偶聯服務。

配方：PBS，pH 6.5

不含穩定劑或防腐劑

內毒素：<2EU/毫克（<0.002EU/微克）

由LAL凝膠凝固測定法確定

純度：>95%

由SDS-PAGE確定

無菌性：0.2微米過濾

在無動物設施中從細胞培養上清液中純化

純化：蛋白質G

分子量：150 kDa

儲存：抗體溶液應以原始濃度在4°C下儲存。不要冷凍。

InVivoMAb大鼠IgG2a同種型對照文獻參考：

Bauche, D., et al. (2018). "LAG3(+) Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1(+) Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis" Immunity 49(2): 342-352 e345.

Ngiow, S. F., et al. (2015). "A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1" Cancer Res 75(18): 3800-3811.

Dai, M., et al. (2015). "Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies" Clin Cancer Res 21(5): 1127-1138.

Kurtulus, S., et al. (2015). "TIGIT predominantly regulates the immune response via regulatory T cells" J Clin Invest. doi : 10.1172/JCI81187.

Ellis, G. T., et al. (2015). "TRAIL+ monocytes and monocyte-related cells cause lung damage and thereby increase susceptibility to influenza-Streptococcus pneumoniae coinfection" EMBO Rep 16(9): 1203-1218.

Walsh, K. B., et al. (2014). "Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy" J Virol 88(11): 6281-6293.